35 related articles for article (PubMed ID: 36367445)
21. Expanding horizons of achondroplasia treatment: current options and future developments.
Fafilek B; Bosakova M; Krejci P
Osteoarthritis Cartilage; 2022 Apr; 30(4):535-544. PubMed ID: 34864168
[TBL] [Abstract][Full Text] [Related]
22. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
23. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.
Wrobel W; Pach E; Ben-Skowronek I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070375
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.
Aviezer D; Golembo M; Yayon A
Curr Drug Targets; 2003 Jul; 4(5):353-65. PubMed ID: 12816345
[TBL] [Abstract][Full Text] [Related]
25. Achondroplasia: from genotype to phenotype.
Richette P; Bardin T; Stheneur C
Joint Bone Spine; 2008 Mar; 75(2):125-30. PubMed ID: 17950653
[TBL] [Abstract][Full Text] [Related]
26. Achondroplasia: pathogenesis and implications for future treatment.
Laederich MB; Horton WA
Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
[TBL] [Abstract][Full Text] [Related]
27. Achondroplasia: Development, pathogenesis, and therapy.
Ornitz DM; Legeai-Mallet L
Dev Dyn; 2017 Apr; 246(4):291-309. PubMed ID: 27987249
[TBL] [Abstract][Full Text] [Related]
28. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
Foldynova-Trantirkova S; Wilcox WR; Krejci P
Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
[TBL] [Abstract][Full Text] [Related]
29. Neurological Manifestations of Achondroplasia.
Bodensteiner JB
Curr Neurol Neurosci Rep; 2019 Nov; 19(12):105. PubMed ID: 31782047
[TBL] [Abstract][Full Text] [Related]
30. Juvenile toxicity study of PF-07256472/recifercept, a recombinant human soluble fibroblast growth factor receptor 3, in 2-3-month-old cynomolgus monkeys.
Campion SN; Bowman CJ; Fuchs A; Karanian D; Rana P; Cappon GD
Birth Defects Res; 2023 Feb; 115(3):348-356. PubMed ID: 36367445
[TBL] [Abstract][Full Text] [Related]
31. FGFR3 targeting strategies for achondroplasia.
Laederich MB; Horton WA
Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
[TBL] [Abstract][Full Text] [Related]
32. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
Legeai-Mallet L
Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
[TBL] [Abstract][Full Text] [Related]
33. Vosoritide: First Approval.
Duggan S
Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
[TBL] [Abstract][Full Text] [Related]
34. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
Tanaka H
Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
[TBL] [Abstract][Full Text] [Related]
35. Achondroplasia.
Horton WA; Hall JG; Hecht JT
Lancet; 2007 Jul; 370(9582):162-172. PubMed ID: 17630040
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]